321 related articles for article (PubMed ID: 26155765)
1. Can pregabalin prevent paclitaxel-associated neuropathy?--An ACCRU pilot trial.
Shinde SS; Seisler D; Soori G; Atherton PJ; Pachman DR; Lafky J; Ruddy KJ; Loprinzi CL
Support Care Cancer; 2016 Feb; 24(2):547-553. PubMed ID: 26155765
[TBL] [Abstract][Full Text] [Related]
2. A pilot study of minocycline for the prevention of paclitaxel-associated neuropathy: ACCRU study RU221408I.
Pachman DR; Dockter T; Zekan PJ; Fruth B; Ruddy KJ; Ta LE; Lafky JM; Dentchev T; Le-Lindqwister NA; Sikov WM; Staff N; Beutler AS; Loprinzi CL
Support Care Cancer; 2017 Nov; 25(11):3407-3416. PubMed ID: 28551844
[TBL] [Abstract][Full Text] [Related]
3. North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study.
Leal AD; Qin R; Atherton PJ; Haluska P; Behrens RJ; Tiber CH; Watanaboonyakhet P; Weiss M; Adams PT; Dockter TJ; Loprinzi CL;
Cancer; 2014 Jun; 120(12):1890-7. PubMed ID: 24619793
[TBL] [Abstract][Full Text] [Related]
4. A pilot randomized, placebo-controlled, double-blind study of omega-3 fatty acids to prevent paclitaxel-associated acute pain syndrome in breast cancer patients: Alliance A22_Pilot2.
Tawfik B; Dayao ZR; Brown-Glaberman UA; Pankratz VS; Lafky JM; Loprinzi CL; Barton DL
Support Care Cancer; 2023 Oct; 31(12):637. PubMed ID: 37847317
[TBL] [Abstract][Full Text] [Related]
5. Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1.
Reeves BN; Dakhil SR; Sloan JA; Wolf SL; Burger KN; Kamal A; Le-Lindqwister NA; Soori GS; Jaslowski AJ; Kelaghan J; Novotny PJ; Lachance DH; Loprinzi CL
Cancer; 2012 Oct; 118(20):5171-8. PubMed ID: 22415454
[TBL] [Abstract][Full Text] [Related]
6. Randomized controlled trial of cryotherapy to prevent paclitaxel-induced peripheral neuropathy (RU221511I); an ACCRU trial.
Ruddy KJ; Le-Rademacher J; Lacouture ME; Wilkinson M; Onitilo AA; Vander Woude AC; Grosse-Perdekamp MT; Dockter T; Tan AD; Beutler A; Loprinzi CL
Breast; 2019 Dec; 48():89-97. PubMed ID: 31590108
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal validation and comparison of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx).
Cheng HL; Molassiotis A
Asia Pac J Clin Oncol; 2019 Feb; 15(1):56-62. PubMed ID: 29873180
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of gabapentin pharmacotherapy in chemotherapy-induced peripheral neuropathy.
Magnowska M; Iżycka N; Kapoła-Czyż J; Romała A; Lorek J; Spaczyński M; Nowak-Markwitz E
Ginekol Pol; 2018; 89(4):200-4. PubMed ID: 29781075
[TBL] [Abstract][Full Text] [Related]
9. The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA.
Wolf SL; Barton DL; Qin R; Wos EJ; Sloan JA; Liu H; Aaronson NK; Satele DV; Mattar BI; Green NB; Loprinzi CL
Support Care Cancer; 2012 Mar; 20(3):625-32. PubMed ID: 21479990
[TBL] [Abstract][Full Text] [Related]
10. Reference data of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 Questionnaire in the general Dutch population.
Mols F; van de Poll-Franse LV; Vreugdenhil G; Beijers AJ; Kieffer JM; Aaronson NK; Husson O
Eur J Cancer; 2016 Dec; 69():28-38. PubMed ID: 27814471
[TBL] [Abstract][Full Text] [Related]
11. Cross-over, open-label trial of the effects of gabapentin versus pregabalin on painful peripheral neuropathy and health-related quality of life in haemodialysis patients.
Atalay H; Solak Y; Biyik Z; Gaipov A; Guney F; Turk S
Clin Drug Investig; 2013 Jun; 33(6):401-8. PubMed ID: 23572323
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).
Rao RD; Michalak JC; Sloan JA; Loprinzi CL; Soori GS; Nikcevich DA; Warner DO; Novotny P; Kutteh LA; Wong GY;
Cancer; 2007 Nov; 110(9):2110-8. PubMed ID: 17853395
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of pregabalin using a flexible, optimized dose schedule in Korean patients with peripheral neuropathic pain: a 10-week, randomized, double-blind, placebo-controlled, multicenter study.
Moon DE; Lee DI; Lee SC; Song SO; Yoon DM; Yoon MH; Kim HK; Lee YW; Kim C; Lee PB
Clin Ther; 2010 Dec; 32(14):2370-85. PubMed ID: 21353106
[TBL] [Abstract][Full Text] [Related]
14. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1.
Loprinzi CL; Reeves BN; Dakhil SR; Sloan JA; Wolf SL; Burger KN; Kamal A; Le-Lindqwister NA; Soori GS; Jaslowski AJ; Novotny PJ; Lachance DH
J Clin Oncol; 2011 Apr; 29(11):1472-8. PubMed ID: 21383290
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy.
Davis ID; Kiers L; MacGregor L; Quinn M; Arezzo J; Green M; Rosenthal M; Chia M; Michael M; Bartley P; Harrison L; Daly M
Clin Cancer Res; 2005 Mar; 11(5):1890-8. PubMed ID: 15756015
[TBL] [Abstract][Full Text] [Related]
16. MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy.
Zimmerman C; Atherton PJ; Pachman D; Seisler D; Wagner-Johnston N; Dakhil S; Lafky JM; Qin R; Grothey A; Loprinzi CL
Support Care Cancer; 2016 Mar; 24(3):1071-8. PubMed ID: 26248652
[TBL] [Abstract][Full Text] [Related]
17. Comparative safety and tolerability of duloxetine vs. pregabalin vs. duloxetine plus gabapentin in patients with diabetic peripheral neuropathic pain.
Irving G; Tanenberg RJ; Raskin J; Risser RC; Malcolm S
Int J Clin Pract; 2014 Sep; 68(9):1130-40. PubMed ID: 24837444
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials.
Le-Rademacher J; Kanwar R; Seisler D; Pachman DR; Qin R; Abyzov A; Ruddy KJ; Banck MS; Lavoie Smith EM; Dorsey SG; Aaronson NK; Sloan J; Loprinzi CL; Beutler AS
Support Care Cancer; 2017 Nov; 25(11):3537-3544. PubMed ID: 28634656
[TBL] [Abstract][Full Text] [Related]
19. Painful and non-painful chemotherapy-induced peripheral neuropathy and quality of life in colorectal cancer survivors: results from the population-based PROFILES registry.
Bonhof CS; Trompetter HR; Vreugdenhil G; van de Poll-Franse LV; Mols F
Support Care Cancer; 2020 Dec; 28(12):5933-5941. PubMed ID: 32281032
[TBL] [Abstract][Full Text] [Related]
20. Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: Findings from a cost-consequences analysis in a nested case-control study.
Pérez C; Navarro A; Saldaña MT; Masramón X; Rejas J
Clin Ther; 2010 Jul; 32(7):1357-70. PubMed ID: 20678683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
